WE ARE THE FIRST TRUE, POINT-OF-NEED, NEXT-GENERATION SEQUENCING COMPANY
Find out more from our Co-Founder, Professor Christofer Toumazou and our CEO, Sam Reed.
Some of DNAe’s development work is funded in whole or in part with Federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract No. HHS0100201600017C.
Diagnostic solutions using fast and powerful genomic analyses.
DNAe is developing the LiDia-SEQ™ Platform, a direct-from-specimen diagnostic system that performs DNA sequencing on a microchip, to provide rapid, actionable information to clinicians. The user-friendly system can operate in a variety of hospital environments at the point-of-need, with flexible levels of throughput to match a wide range of clinical demands.
Our initial focus is on infectious disease diagnostics, where speed and microbial DNA sequence information can make the difference between life and death. This includes a range of tests, starting with a groundbreaking test for bloodstream infections (BSI) and antimicrobial resistance (AMR), which uses whole blood specimens to detect and identify infections that lead to sepsis.
To follow this, we have a growing pipeline of tests for other healthcare applications where rapid point-of-need diagnostics are of critical need, including infectious diseases and cancer testing and monitoring.
For Research Use Only. Not for use in diagnostic procedures.
For illustrative purposes only.
INFECTIOUS DISEASE AND ANTIMICROBIAL RESISTANCE.
In September 2016, DNAe was awarded a contract worth up to $51.9M by the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) in the US Health and Human Services (HHS), to develop its semiconductor sequencing diagnostic platform initially for antimicrobial resistant infections. We reported successful completion of the first phase of development in late 2018 and are now approaching completion of the second phase.
identify the infection faster
Results in 3-4 hours
Results in 2-6 days
It can take 2-6 days to diagnose bloodstream infections using a blood culture test. Using our LiDia-SEQ™ sequencing system and BSI/AMR test, this can be achieved in approximately 3-4 hours, directly from raw specimens.
Bringing Cutting-Edge Technology to the Patient
For Research Use Only. Not for use in diagnostic procedures.
For illustrative purposes only.
Currrent vacancies
Work with us
AND BEGIN A FASCINATING JOURNEY OF DISCOVERY
We are creating radically different products that change the game for early diagnosis and monitoring of potentially fatal diseases. The work we do at DNAe helps save lives, this is a powerful motivator and a fantastic reason to get involved.
